AstraZeneca’s Tagrisso is already rolling in EGFR-mutated lung cancer, but new survival data could help spur additional reimbursement. Saturday at the European Society for Medical Oncology annual meeting, the British drugmaker touted results showing that using Tagrisso instead of older TKI inhibitors could cut patients’ risk of death by 20%.
